Skip to main content
SpringerLink
Log in

Vancomycin Serum Concentration Monitoring

The Middle Ground is Best

  • Clinical Pharmacokinetics
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Summary

The recent increase in the use of vancomycin has led to renewed interest in its pharmacokinetics, and, in particular, the importance of monitoring serum drug concentrations. A review of the literature and evaluation of pharmacokinetic data from Vancouver Hospital and Health Sciences Centre demonstrated that vancomycin meets the criteria necessary for serum drug concentration monitoring. These include the availability of a sensitive and specific assay, substantial interpatient and intrapatient variability in drug disposition, and evidence suggesting a correlation between vancomycin serum concentration and both efficacy and toxicity. A review of vancomycin disposition data for 371 consecutive treatment courses at this hospital revealed significant interpatient variability in drug clearance and volume of distribution. Accordingly, it would be difficult to accurately predict the change in serum concentration resulting from a given vancomycin dose. There appears to be less intrapatient variability in volume of distribution; however, serum elimination half-life tends to increase during treatment, necessitating an alteration in dose interval. Although convenient, physiological parameters to monitor serum creatinine concentration and bodyweight are not accurate predictors of drug clearance and volume of distribution. Serum concentration monitoring is also necessary to ensure that vancomycin concentrations are in excess of the minimum inhibitory concentration of the organism at all times during treatment. Although a causal relationship between vancomycin and toxicity has been difficult to prove, there is some evidence in the literature to support a relationship between high troughs and nephrotoxicity. In view of the available evidence, we do not believe that serum concentration monitoring should be totally abandoned. We have created empiric dosage guidelines and a decision-making algorithm for serum drug concentration monitoring that have streamlined the process of drug prescribing and monitoring at this institution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cunha BA, Ristuccia AM. Clinical usefulness of vancomycin. Clin Pharm 1983; 2: 417–24

    PubMed  CAS  Google Scholar 

  2. Louria DB, Kaminski T, Buchman J. Vancomycin in severe staphylococcal infections. Arch Intern Med 1961; 107: 225–40

    Article  PubMed  CAS  Google Scholar 

  3. Woodley DW, Hall WH. The treatment of severe staphylococcal infections with vancomycin. Ann Intern Med 1961; 55: 235–49

    PubMed  CAS  Google Scholar 

  4. Downs NJ, Neihart RE, Dolezal JM, et al. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989; 149: 1777–81

    Article  PubMed  CAS  Google Scholar 

  5. Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991; 115: 739–41

    PubMed  CAS  Google Scholar 

  6. Cheung RPF, DiPiro JT. Vancomycin: an update. Pharmacotherapy 1986; 6: 153–69

    PubMed  CAS  Google Scholar 

  7. Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting proof of its value. Clin Pharm 1987: 6: 652–4

    PubMed  CAS  Google Scholar 

  8. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533–43

    Article  PubMed  CAS  Google Scholar 

  9. Shafran SD, Conly JM. The serum vancomycin assay: a test of historic interest. Can J Infect Dis 1995; 6: 67–8

    PubMed  CAS  Google Scholar 

  10. Moellering RC. Monitoring serum vancomycin levels: Climbing the mountain because it is there? Clin Infect Dis 1994; 18: 544–6

    Article  PubMed  Google Scholar 

  11. Shalansky S. Rationalization of vancomycin serum concentration monitoring. Can J Hosp Pharm 1995; 48: 17–24

    Google Scholar 

  12. Conly JM, Gold W, Shafran SD. Once-daily aminoglycoside dosing: a new look at an old drug. Can J Infect Dis 1994; 5: 905–6

    Google Scholar 

  13. Peck CC, Rodman JH. Analysis of clinical pharmacokinetic data for individualizing drug dosage regimens. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: Principles of therapeutic drug monitoring. 2nd ed. Spokane: Applied Therapeutics 986: 55–82

  14. Matzke GR. Vancomycin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: Principles of therapeutic drug monitoring. 2nd ed. Spokane: Applied Therapeutics 986: 399–436

  15. Pfaller MA, Krogstad DJ, Granich GG, et al. Laboratory evaluation of five assay methods of vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay. J Clin Microbiol 1984; 20: 311–6

    PubMed  CAS  Google Scholar 

  16. Ackerman BH, Berg HG, Strate RG, et al. Comparison of radioimmunoassay and fluorescent polarization immunoassay for quantitative determination of vancomycin concentrations in serum. J Clin Microbiol 1983; 18: 994–5

    PubMed  CAS  Google Scholar 

  17. Filburn BH, Shull VH, Tempera YM, et al. Evaluation of an automated fluorescence polarization immunoassay for vancomycin. Antimicrob Agents Chemother 1983; 24: 216–20

    Article  PubMed  CAS  Google Scholar 

  18. Schwenzer KS, Wang CJ, Anhalt JP, et al. Automated fluorescence polarization immunoassay for monitoring vancomycin. Ther Drug Monit 1983; 5: 341–5

    Article  PubMed  CAS  Google Scholar 

  19. Pohlad DJ, Saravolatz LD, Somerville MM. Comparison of fluorescence polarization immunoassay and bioassay of vancomycin. J Clin Microbiol 1984; 20: 159–61

    Google Scholar 

  20. Healy DP, Polk RE, Garson ML, et al. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal healthy volunteers. Antimicrob Agents Chemother 1987; 31: 393–7

    Article  PubMed  CAS  Google Scholar 

  21. Healy DP, Sahai JV, Fuller SH, et al. Vancomycin induced histamine release and ‘red man syndrome’: comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother 1990; 34: 550–4

    Article  PubMed  CAS  Google Scholar 

  22. Banner W, Ray CG. Vancomycin in perspective. Am J Dis Child 1984; 138: 14–6

    PubMed  Google Scholar 

  23. Moellering RC. Pharmacokinetics of vancomycin. J Antimicrob Agents Chemother 1984; 14: Suppl. D: 43–52

    CAS  Google Scholar 

  24. Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25: 433–7

    Article  PubMed  CAS  Google Scholar 

  25. Moellering RC, Krogstad DJ, Greenblatt DJ. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis 1981; 3Suppl.: S230–235

    PubMed  Google Scholar 

  26. Rotschafer JC, Crossley K, Zaske DE, et al. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982; 22: 391–4

    Article  PubMed  CAS  Google Scholar 

  27. Moellering RC, Krogstad DJ, Greenblatt DJ, et al. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94: 343–6

    PubMed  Google Scholar 

  28. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 32: 848–52

    Article  PubMed  CAS  Google Scholar 

  29. Cutler NR, Narang PK, Lesko LJ, et al. Vancomycin disposition: the importance of age. Clin Pharmacol Ther 1984; 36: 803–10

    Article  PubMed  CAS  Google Scholar 

  30. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994; 16: 513–8

    Article  PubMed  CAS  Google Scholar 

  31. Schaad UB, McCracken GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119–26

    Article  PubMed  CAS  Google Scholar 

  32. Gross JR, Kaplan SL, Kramer WG, et al. Vancomycin pharmacokinetics in premature infants. Pediatr Pharmacol 1985; 5: 17–22

    CAS  Google Scholar 

  33. Spivey JM, Gal P. Vancomycin pharmacokinetics in neonates. Am J Dis Child 1986; 140: 859

    PubMed  CAS  Google Scholar 

  34. Naqvi SH, Keenan WJ, Reichley RM, et al. Vancomycin pharmacokinetics in small, seriously ill infants. Am J Dis Child 1986; 140: 107–10

    PubMed  CAS  Google Scholar 

  35. Schaible DH, Rocci ML, Alpert GA, et al. Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Ped Infect Dis 1986; 5: 304–8

    Article  CAS  Google Scholar 

  36. Reed MD, Kliegman RM, Weiner JS, et al. The clinical pharmacology of vancomycin in seriously ill preterm infants. Ped Res 1987; 22: 360–3

    Article  CAS  Google Scholar 

  37. James A, Koren G, Milliken J, et al. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987; 31: 52–4

    Article  PubMed  CAS  Google Scholar 

  38. Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 1994; 56: 169–75

    Article  PubMed  CAS  Google Scholar 

  39. Lisby-Sutch SM, Nahata MC. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988; 35: 637–42

    Article  PubMed  CAS  Google Scholar 

  40. Leonard AE, Boro MS. Vancomycin pharmacokinetics in middle-aged and elderly men. Am J Hosp Pharm 1994; 51: 798–800

    PubMed  CAS  Google Scholar 

  41. Guay DR, Vance-Bryan K, Gilliland S, et al. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol 1993; 33: 918–22

    PubMed  CAS  Google Scholar 

  42. Macias WL, Mueller BA, Scarim SK, et al. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther 1991; 50: 688–94

    Article  PubMed  CAS  Google Scholar 

  43. Fernandez de Gatta MM, Fruns I, Dominguez-Gil A. Individualizing vancomycin dosing regimens: an evaluation of two pharmacokinetic dosing programs in critically ill patients. Pharmacotherapy 1994; 14: 196–201

    Google Scholar 

  44. Garaud JJ, Regnier B, Inglebert F, et al. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother 1984; 14Suppl. D: 53–7

    PubMed  Google Scholar 

  45. Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther 1988; 44: 9–13

    Article  PubMed  CAS  Google Scholar 

  46. Brater DC, Bawdon RE, Anderson SA, et al. Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther 1986; 39: 631

    Article  PubMed  CAS  Google Scholar 

  47. Cairns B, Jewesson P. Vancomycin disposition in leukemic patients. Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract 1337]. ICAAC, Houston, Texas, 1989

    Google Scholar 

  48. Cairns B, Jewesson PJ. Vancomycin. Vancouver General Hospital Drug Information Supplement 1990; 7: 1–4

    Google Scholar 

  49. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41

    Article  Google Scholar 

  50. Nimmo CR, Mamdani F, Baker A, et al. Development and implementation of simplified aminoglycoside empiric dosing guidelines. Pharmacotherapy 1993; 13: 408–14

    Google Scholar 

  51. Vance-Bryan K, Guay DR, Gilliland SS, et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 37: 436–40

    Article  PubMed  CAS  Google Scholar 

  52. Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575–80

    Article  PubMed  CAS  Google Scholar 

  53. Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. Part IV: vancomycin. Clin Pharmacokinet 1991; 20: 463–76

    Article  PubMed  CAS  Google Scholar 

  54. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic monitoring: is it necessary? Ann Pharmacother 1993; 27: 594–8

    PubMed  CAS  Google Scholar 

  55. Sorrell TC, Packham DR, Shanker S, et al. Vancomycin therapy for methicillin resistant Staphylococcus aureus. Ann Intern Med 1982; 97: 344–50

    PubMed  CAS  Google Scholar 

  56. Viladrich PF, Gudiol F, Linares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991; 35: 2467–72

    Article  PubMed  CAS  Google Scholar 

  57. Cafferkey MT, Hone R, Keane CT. Severe staphylococcal infections treated with vancomycin. J Antimicrob Chemother 1982; 9: 69–74

    Article  PubMed  CAS  Google Scholar 

  58. Leader WG, Chandler MH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995; 28: 327–42

    Article  PubMed  CAS  Google Scholar 

  59. Peetermans WE, Hoogeterp JJ, Hazekamp-Van Dokkum AM, et al. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990; 34: 1869–74

    Article  PubMed  CAS  Google Scholar 

  60. Watanakunakorn C. The antibacterial action of vancomycin. Rev Infect Dis 1981; 3Suppl.: S210–215

    PubMed  Google Scholar 

  61. Tuazon CU, Miller H. Comparative in vitro activities of teicoplanin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci. Antimicrob Agents Chemother 1984; 25: 411–2

    Article  PubMed  CAS  Google Scholar 

  62. Uttley AHC, Collins CH, Naidoo J, et al. Vancomycin-resistant enterococci. Lancet 1988; 1: 57–8

    Article  PubMed  CAS  Google Scholar 

  63. Shlaes DM, Binczewski B, Rice LB. Emerging antimicrobial resistance and the immunocompromised host. Clin Infect Dis 1993; 17Suppl.: S527–536

    Article  PubMed  Google Scholar 

  64. Handwerger S, Perlman DC, Altarac D, et al. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis 1992; 14: 655–61

    Article  PubMed  CAS  Google Scholar 

  65. Hayden M, Koenig G, Harris A, et al. Emergence of high-level vancomycin resistance in enterococci from two neighbouring hospitals, [abstract no. 984]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1991

    Google Scholar 

  66. Livornese LL, Dias S, Samel C, et al. Hospital acquired infection with vancomycin resistant Enterococci fecium transmitted by electronic thermometers. Ann Intern Med 1992; 117: 112–6

    PubMed  Google Scholar 

  67. Geraci JE, Heilman FR, Nichols DR, et al. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Mayo Clin Proc 1956; 31–564–82

    Google Scholar 

  68. Redfield D, Underman A, Norman D, et al. CSF penetration of vancomycin In bacterial meningitis. In: Nelson JD, Grassi C, editors. Current chemotherapy and infectious disease proceedings. 11th ICC and 19th ICMC, 1980; 1: 628–40

    Google Scholar 

  69. Nolan CM, Flanigan WJ, Rastogi SP, et al. Vancomycin penetration into CSF during treatment of patients receiving haemodialysis. South Med J 1980; 73: 1333–8

    Article  PubMed  CAS  Google Scholar 

  70. Massias L, Dubois C, DeLentdecker P, et al. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 1992; 36: 2539–41

    Article  PubMed  CAS  Google Scholar 

  71. Farber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138–41

    Article  PubMed  CAS  Google Scholar 

  72. Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679–87

    Article  PubMed  CAS  Google Scholar 

  73. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325–34

    Article  PubMed  CAS  Google Scholar 

  74. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteraemia. Pharmacotherapy 1995; 15: 85–91

    PubMed  CAS  Google Scholar 

  75. Cimino MA, Rotstein C, Slaughter RL, et al. Relationship of serum antibiotic concentrations to nephrotoxicity in hematology patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987; 83: 1091–7

    Article  PubMed  CAS  Google Scholar 

  76. Pauly DJ, Musa DM, Lestico MR, et al. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990; 10: 378–82

    PubMed  CAS  Google Scholar 

  77. Rodvold KA, Zokufa H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm 1987; 6: 655–8

    PubMed  CAS  Google Scholar 

  78. Lake KD, Peterson CD. Evaluation of a method for initiating vancomycin therapy: experience in 205 patients. Pharmacotherapy 1988; 8: 284–6

    PubMed  CAS  Google Scholar 

  79. McCormack JP, Lynd LD, Pfeifer NM. Vancomycin cost containment through a therapeutic and pharmacokinetic drug monitoring service. Can J Hosp Pharm 1989; 42: 3–9

    Google Scholar 

  80. Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994; 28: 1335–9

    PubMed  CAS  Google Scholar 

  81. McCormack JP, Jewesson PJ. A critical reevaluation of the ‘therapeutic range’ of aminoglycosides. Clin Infect Dis 1992; 14: 320–39

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Vancouver Hospital and Health Sciences Centre, 855 W. 12th Avenue, Vancouver, BC V5Z 1M9, Canada

    F. Marra

  2. Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

    B. Cairns

  3. Faculty of Pharmaceutical Sciences, University of British Columbia; Department of Pharmacy and Division of Infectious Diseases, Vancouver Hospital and Health Sciences Centre, Vancouver, Canada

    P. Jewesson

Authors
  1. F. Marra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Cairns
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Jewesson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Jewesson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marra, F., Cairns, B. & Jewesson, P. Vancomycin Serum Concentration Monitoring. Clinical Drug Investigation 12, 105–118 (1996). https://doi.org/10.2165/00044011-199612020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-199612020-00006

Keywords

Search

Navigation